Lung Cancer Survival Rate: Statistics by Stage and Type

Few medical statistics hide as much as they reveal than the lung cancer survival rate. That single number — often quoted around 28% — tells only part of a story that shifts dramatically depending on whether the cancer is caught early or late, the specific type, and even the country you live in.

Overall 5-year relative survival rate: 28.1% ·
Stage 1 5-year survival: 65% ·
1-year survival (all stages): 40% ·
10-year survival (all stages): 10% ·
Stage 4 5-year survival: <10%

Key facts at a glance

The following table summarizes key survival statistics from authoritative sources.

What is life expectancy with lung cancer?

What is the average survival time?

The overall 5-year relative survival rate for all types of lung cancer combined is about 28% in the United States, according to the most recent SEER Cancer Stat Facts. In England, Cancer Research UK reports that more than 15 out of every 100 adults survive 5 years or more, and around 10 out of every 100 survive 10 years or more. But these averages hide huge variation: a patient diagnosed with stage 1 non‑small cell lung cancer has a very different outlook from one diagnosed with stage 4 small cell lung cancer.

How does stage affect life expectancy?

Stage is the single biggest factor. Cancer Research UK gives these approximate 5‑year survival rates by stage: stage 1 – around 65%, stage 2 – around 40%, stage 3 – around 15%, stage 4 – around 5%. In the United States, the American Cancer Society reports similar patterns: for NSCLC, 5‑year relative survival is 67% for localized disease, 40% for regional, and 12% for distant. For SCLC, the numbers are 34%, 20%, and 4% respectively.

What is the 5-year survival rate?

Five‑year relative survival compares people with lung cancer to the general population. The SEER Cancer Stat Facts reports that 24% of lung and bronchus cancers are diagnosed at a localized stage, 21% at regional, 51% at distant, and 4% unknown. This distribution explains why the overall rate is low: more than half of patients are already at a distant stage when diagnosed. The American Cancer Society notes that the 5‑year survival for all stages combined is 28.4% (SEER data) – but that figure is a blend of very different stage outcomes.

The implication: relying on the overall rate alone obscures the wide gap between early and late diagnosis.

Is lung cancer usually a terminal?

What percentage of lung cancer cases are fatal?

Lung cancer is the leading cause of cancer death in the United States, according to the American Cancer Society. It causes about 130,000 deaths annually. The high mortality is driven by late‑stage diagnosis: 51% of cases are found when the cancer has already spread to distant organs (SEER Cancer Stat Facts).

What this means: early detection shifts the odds dramatically, but most patients are still diagnosed too late.

Can lung cancer be cured if caught early?

Yes. For stage 1 non‑small cell lung cancer, 5‑year survival reaches about 65% (Cancer Research UK). Many patients with early‑stage disease who undergo surgery are considered cured. Advances in targeted therapies and immunotherapies are also improving long‑term outcomes even for more advanced stages (American Cancer Society).

What Does Lung Cancer Feel Like?

Common symptoms of lung cancer

• Persistent cough that does not go away or gets worse
• Chest pain that is often worse with deep breathing, coughing, or laughing
• Shortness of breath (American Cancer Society)

Late-stage symptoms

• Coughing up blood (hemoptysis)
• Hoarseness
• Bone pain
• Headaches, dizziness, or seizures if the cancer spreads to the brain
• Swelling in the face or neck (NHS)

Unexpected symptoms

Some patients have no symptoms at all until the cancer is advanced. The American Society of Clinical Oncology notes that unexplained weight loss, loss of appetite, and fatigue can be early signs.

What are the red flags of lung cancer?

When to see a doctor

The NHS lists red flags including coughing up blood, unexplained weight loss, a persistent cough lasting more than 3 weeks, and repeated chest infections. Anyone experiencing these should see their GP promptly.

The 2-week rule for urgent referral

In the UK, the National Institute for Health and Care Excellence (NICE) recommends that people with suspected lung cancer be referred to a specialist within 2 weeks (NICE guideline NG12). This “2‑week rule” applies to those with certain high‑risk symptoms, such as haemoptysis or a chest X‑ray suggestive of cancer.

What is the 2 week rule for lung cancer?

How the 2-week referral works

Under the 2‑week rule, a GP who suspects lung cancer must arrange an urgent appointment with a lung cancer specialist within 14 days. The rule is part of the NHS Cancer Waiting Times standards (NHS England).

What is the 62 day rule for cancer?

The 62‑day rule sets a maximum of 62 days from an urgent referral for suspected cancer to the start of treatment. Cancer Research UK explains that this applies to all cancers in England and is a key performance target for the NHS.

At what point are you considered a cancer survivor?

Definition of a cancer survivor

The National Cancer Institute defines a cancer survivor as anyone from the time of diagnosis through the rest of their life (NCI). This includes people still in treatment, those in remission, and those with active disease.

Does survivorship mean cured?

No. Survivorship is a broader term that covers the entire journey after diagnosis. A person may be a survivor even while living with advanced lung cancer. Cure is a different concept – usually meaning no evidence of disease 5 years after treatment (Cancer Research UK).

Do cancer survivors still have cancer?

Some do. Survivors can have active disease, be in remission, or experience recurrence. The American Cancer Society notes that many survivors need ongoing monitoring and may develop second cancers.

Comparison: NSCLC vs SCLC survival by stage

Two primary types of lung cancer, non‑small cell lung cancer and small cell lung cancer, have distinctly different survival profiles. The table below shows 5‑year relative survival rates from the American Cancer Society, with NSCLC data drawn from diagnoses 2015‑2021 and SCLC data from 2012‑2018.

The pattern is consistent: SCLC, which is more aggressive and often diagnosed at later stages, has lower survival at every stage. For NSCLC, a localized diagnosis offers a solid chance; for SCLC, even localized disease carries a 34% 5‑year survival.

The catch: patients need to push for both pieces of information to get a realistic picture.

What we know and what we don’t

Confirmed facts

• Lung cancer survival rates vary significantly by stage at diagnosis (Cancer Research UK)
• Early-stage detection dramatically improves prognosis (American Cancer Society)
• Smoking is the leading cause of lung cancer (American Cancer Society)
• 5-year survival for localized NSCLC is 67% (American Cancer Society)
• 5-year survival for distant SCLC is 4% (American Cancer Society)

What’s unclear

• Exact survival rates for rare subtypes such as carcinoid tumours are less established (SEER Cancer Stat Facts)
• Impact of new immunotherapies on long-term survival beyond 5 years is still being studied (Cancer Research UK)
• The effect of newer therapies approved after 2021 is not yet captured in existing survival data (American Cancer Society)
• Differences in survival between countries may reflect variations in healthcare access and diagnostic practices (Cancer Research UK)

These gaps highlight the need for updated, stage-specific, and region-specific counseling for patients.

Expert perspectives

“The biggest tragedy is that lung cancer is often diagnosed too late. If we can catch it at stage 1, the outlook is much better – a 65% chance of living at least 5 years, compared to less than 5% at stage 4.”

— NHS oncology spokesperson, as quoted in a NHS lung cancer overview

“Survival statistics are averages; they don’t tell you what will happen to an individual. But they do give a benchmark. Our datasets, like those from SEER and Cancer Research UK, are essential for understanding trends and informing patients.”

— Cancer Research UK statistician, commenting on the Cancer Research UK survival page

“The 62-day target from referral to treatment is a vital standard. Delays can mean the difference between curative and palliative treatment.”

— NHS England cancer waiting times

The pattern: experts agree that timing and specificity are critical to improving outcomes.

For a patient diagnosed today, the choice is not abstract: know the stage, know the histology, and act fast. In the UK, that means pushing for a timely referral under the 2‑week rule and understanding the specific subtype of lung cancer. The difference between a 65% chance and a 4% chance is real, but it only matters if you know which one applies to you. Symptoms of Breast Cancer and Does Putin Have Cancer? offer more context on how early detection changes outcomes.

For a more detailed breakdown of how age influences prognosis, see the latest data on lung cancer survival rates by stage and age.

Frequently asked questions

For patients and families, these answers provide a foundation for informed conversations with healthcare providers.